ACAD
Price
$21.57
Change
-$0.54 (-2.44%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
3.61B
29 days until earnings call
AURA
Price
$6.26
Change
-$0.02 (-0.32%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
388.15M
37 days until earnings call
Interact to see
Advertisement

ACAD vs AURA

Header iconACAD vs AURA Comparison
Open Charts ACAD vs AURABanner chart's image
ACADIA Pharmaceuticals
Price$21.57
Change-$0.54 (-2.44%)
Volume$24.08K
Capitalization3.61B
Aura Biosciences
Price$6.26
Change-$0.02 (-0.32%)
Volume$2.66K
Capitalization388.15M
ACAD vs AURA Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. AURA commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and AURA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (ACAD: $21.57 vs. AURA: $6.26)
Brand notoriety: ACAD and AURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 71% vs. AURA: 57%
Market capitalization -- ACAD: $3.61B vs. AURA: $388.15M
ACAD [@Biotechnology] is valued at $3.61B. AURA’s [@Biotechnology] market capitalization is $388.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileAURA’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • AURA’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than AURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 3 TA indicator(s) are bullish while AURA’s TA Score has 3 bullish TA indicator(s).

  • ACAD’s TA Score: 3 bullish, 6 bearish.
  • AURA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, AURA is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -4.05% price change this week, while AURA (@Biotechnology) price change was +1.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.71%. For the same industry, the average monthly price growth was +31.96%, and the average quarterly price growth was +6.11%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

AURA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.61B) has a higher market cap than AURA($388M). ACAD YTD gains are higher at: 20.545 vs. AURA (-23.601). ACAD has higher annual earnings (EBITDA): 102M vs. AURA (-101.63M). ACAD has more cash in the bank: 682M vs. AURA (128M). AURA has less debt than ACAD: AURA (18.4M) vs ACAD (56M). ACAD has higher revenues than AURA: ACAD (996M) vs AURA (0).
ACADAURAACAD / AURA
Capitalization3.61B388M930%
EBITDA102M-101.63M-100%
Gain YTD20.545-23.601-87%
P/E Ratio15.74N/A-
Revenue996M0-
Total Cash682M128M533%
Total Debt56M18.4M304%
FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADAURA
RSI
ODDS (%)
Bearish Trend 5 days ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
66%
Bullish Trend 5 days ago
83%
Momentum
ODDS (%)
Bullish Trend 5 days ago
79%
Bearish Trend 5 days ago
86%
MACD
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 5 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
70%
Bullish Trend 5 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
75%
Bullish Trend 5 days ago
74%
Advances
ODDS (%)
Bullish Trend 14 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
72%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 5 days ago
88%
Aroon
ODDS (%)
Bullish Trend 5 days ago
65%
Bullish Trend 5 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SAFRY80.051.50
+1.91%
Safran SA
WKCMF72.25N/A
N/A
Wacker Chemie AG
AHAHF3.20N/A
N/A
DESIGN MILK CO LTD.
PMNXF2.20N/A
-0.16%
Perseus Mining Ltd
BIXT0.11-0.01
-5.70%
Bioxytran, Inc.

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with INZY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-0.41%
INZY - ACAD
50%
Loosely correlated
-0.25%
AURA - ACAD
45%
Loosely correlated
-0.16%
CRSP - ACAD
43%
Loosely correlated
N/A
PGEN - ACAD
40%
Loosely correlated
-1.40%
PRME - ACAD
40%
Loosely correlated
-8.68%
More

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with MGTX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
-0.16%
MGTX - AURA
53%
Loosely correlated
-0.90%
VRDN - AURA
51%
Loosely correlated
-1.37%
IDYA - AURA
51%
Loosely correlated
-4.13%
BEAM - AURA
50%
Loosely correlated
-1.98%
CCCC - AURA
48%
Loosely correlated
-7.89%
More